Sartorius, a leading international laboratory and process technology provider, published its nine-month results for 2010. Both Group divisions posted strong gains in order intake, reporting a solid order backlog in light of the last quarter of this year. Sales revenue also showed strong development that was reflected by the overproportionate increase in operating earnings, which were around a third higher than a year ago. On the basis of these positive results, management reaffirms its 2010 growth forecast for the Group and has slightly raised its profit guidance for the full year.
The Biotechnology Division, which operates under the name of Sartorius Stedim Biotech, increased its order intake in the first nine months by 9.1 % (constant currencies: +6.4 %) to 330.9 million euros, up from 303.4 million euros a year earlier. Sales revenue rose in the same period by 7.0 % (constant currencies: +4.6 %) to 318.8 million euros from 298.0 million euros a year ago.
In the first nine months of 2010, the Mechatronics Division received orders valued at 177.4 million euros, up from 151.4 million euros a year earlier. Thus, the division considerably boosted its order intake by 17.2 % (constant currencies: +14.1 %) over its weak year-earlier figure that was due to the crisis. The Mechatronics Division.s sales revenue also recovered significantly by 11.4 %, rising from 146.8 million euros to 163.6 million euros (constant currencies: +8.5 %).
On the whole, the Sartorius Group received orders valued at 508.3 million euros in the first nine months, up from 454.8 million euros a year earlier. This equates to a gain of 11.8 %(constant currencies: +9.0 %). Consolidated nine-month sales revenue rose 8.5 % (constant currencies: +5.9 %) to 482.3 million euros, up from 444.7 million euros a year ago.